Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $68.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 43.70% from the stock’s current price.

A number of other research firms have also weighed in on HALO. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. JMP Securities raised their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $58.00 to $62.00 in a report on Monday, October 7th. Finally, Piper Sandler raised their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Trading Up 1.0 %

Shares of HALO stock opened at $47.32 on Wednesday. The business has a 50-day moving average of $51.03 and a 200 day moving average of $54.04. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics has a 1-year low of $33.15 and a 1-year high of $65.53. The stock has a market capitalization of $6.02 billion, a PE ratio of 15.67, a P/E/G ratio of 0.43 and a beta of 1.23.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total value of $525,800.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares in the company, valued at approximately $35,583,199.52. This represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 30,000 shares of company stock valued at $1,621,800. 2.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds have recently modified their holdings of HALO. International Assets Investment Management LLC purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $33,000. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $49,000. GAMMA Investing LLC lifted its holdings in shares of Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 350 shares during the last quarter. Toth Financial Advisory Corp bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $57,000. Finally, FSC Wealth Advisors LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $65,000. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.